ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma

This study is testing a new combination treatment for advanced liver cancer (hepatocellular carcinoma, or HCC): an experimental drug called ABX196, which activates a special group of immune cells (natural killer T cells), combined with nivolumab (a standard immunotherapy drug). The goal is to see if this combination safely enhances the immune system's ability to attack liver tumors. **You may be eligible if...** - You are 18 or older with HCC that cannot be cured by surgery or local treatment - Your cancer has grown or spread despite prior treatment with sorafenib or lenvatinib, or you could not tolerate these drugs - You have received at least one prior systemic treatment for HCC - You have measurable disease on imaging - Your liver function is well preserved (Child-Pugh class A) - You have no history of confusion caused by liver failure or significant abdominal fluid buildup **You may NOT be eligible if...** - You have active autoimmune disease requiring treatment - You have serious infections including HIV, hepatitis B, or active hepatitis C - You are pregnant or breastfeeding - Your liver function or organ health does not meet required standards Talk to your doctor to see if this trial is right for you.